Article information
Full text is only aviable in PDF
References
[1.]
Macfarlane JT, Boswell T, Douglas G, Finch R, Holmes B, Honeybourne D, et al. BTS guidelines of the management of community-acquired pneumonia in adults – 2004 update [accessed 01/04/09]. Available from: http://www.brit-thoracic.org/guidelines
[2.]
J.U. Hedlund, L.O. Hansson.
Procalcitonin and C-reactive levels in community-acquired pneumonia: correlation with etiology and prognosis.
Infection, 28 (2000), pp. 68-73
[3.]
R. Menéndez, M. Cavalcanti, R. Reyes, J. Mensa, R. Martínez, M.A. Marcos, et al.
Markers of treatment failure in hospitalised community acquired pneumonia.
Thorax, 63 (2008), pp. 447-452
[4.]
L. Alfageme, J. Aspa, S. Bello, J. Blanquer, R. Blanquer, L. Borderías, et al.
Normativas para el diagnóstico y el tratamiento de la neumonía adquirida en la comunidad. Sociedad Española de Neumología y Cirugía Torácica (SEPAR).
Arch Bronconeumol, 41 (2005), pp. 272-289
[5.]
H. Bruunsgaard, A.N. Pedersen, M. Schroll, P. Skinhoj, B.K. Pedersen.
Impaired production of proinflammatory cytokines in response to lipopolysaccharide (LPS) stimulation in elderly humans.
Clin Exp Immunol, 118 (1999), pp. 235-241
[6.]
J.D. Chalmers, A. Singanayagam, A.T. Hill.
C-reactive protein is an independent predictor of severity in community-acquired pneumonia.
Am J Med, 121 (2008), pp. 219-225
Copyright © 2010. Sociedad Española de Neumología y Cirugía Torácica
